Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agilon Health (AGL) Other Accumulated Expenses (2020 - 2025)

Agilon Health's Other Accumulated Expenses history spans 6 years, with the latest figure at $929.8 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses changed 0.2% year-over-year to $929.8 million; the TTM value through Dec 2025 reached $929.8 million, changed 0.2%, while the annual FY2025 figure was $929.8 million, 0.2% changed from the prior year.
  • Other Accumulated Expenses reached $929.8 million in Q4 2025 per AGL's latest filing, down from $1.1 billion in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $1.3 billion in Q1 2024 to a low of $44.1 million in Q4 2021.
  • Average Other Accumulated Expenses over 5 years is $695.3 million, with a median of $837.7 million recorded in 2023.
  • Peak YoY movement for Other Accumulated Expenses: plummeted 34.18% in 2021, then skyrocketed 1929.77% in 2024.
  • A 5-year view of Other Accumulated Expenses shows it stood at $44.1 million in 2021, then grew by 4.08% to $45.9 million in 2022, then changed by 0.0% to $45.9 million in 2023, then surged by 1929.77% to $931.7 million in 2024, then dropped by 0.2% to $929.8 million in 2025.
  • Per Business Quant, the three most recent readings for AGL's Other Accumulated Expenses are $929.8 million (Q4 2025), $1.1 billion (Q3 2025), and $1.0 billion (Q2 2025).